Cancer genomics can guide personalized treatment plans. For example, patients with BRCA mutations may benefit from PARP inhibitors, a class of drugs that target cancer cells with DNA repair deficiencies. Similarly, identifying specific mutations can help in selecting appropriate targeted therapies and immunotherapies.
